Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
These were compared with 245 sites in 49 patients without bone metastases in the Control group.Need captionVariablePCa without bone mets N = 49PCa with bone mets N = 29P valueAge, years (range)74 (53 to 87)71 (52 to 83)0.072BMI (range)23.4 (17.8 to 27.5)22.8 (17.5 to 29.4)0.420Performance status (%)041 (83.7)13 (44.8)0.001*16 (12.2)14 (48.3)22 (4.1)2 (69)Median PSA, ng/mL (range)10.2 (0.3 to 302)269 (0.17 to 5376) < 0.001*Gleason grade group (%)1 or 28 (16.3)00.001*313 (26.5)1 (3.4)415 (30.6)17 (58.6)513 (26.5)13 (37.9)DM (%)2 (4.1)3 (10.3)0.355Habitual drinking (%)11 (22.4)11 (37.9)0.194Current smoking (%)4 (8.2)5 (17.2)0.280Median BAP, μg/L (range)12.2 (4.3 to 26.9)29.6 (7.2 to 567) < 0.001*Median 25(OH)D, pg/mL (range)20.4 (4.6 to 41.2)17.1 (4.4 to 47.8)0.198Free testosterone, pg/mL (range)5.1 (2.0 to 13.4)3.62 (1.2 to 8.5) < 0.001*Androgen-receptor inhibitorBicalutamide49 (100)10 (34.5) < 0.001*Abiraterone03 (9.1)Apalutamide016 (55.2)CHAARTED volume criteriaNo metastasis47 (95.9)0 < 0.001*Low1 (2.0)9 (31.0)High1 (2.0)20 (69.0)Bone metastatic siteL209 (31.0)-L308 (27.6)-L409 (31.0)-Total hip06 (20.7)-Femoral neck03 (10.3)-Others033 (100)-PCa prostate cancer, BMI body mass index, PSA prostate-specific antigen, BAP bone-type alkaline phosphatase*Significant
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions
Observational study · International Journal of Clinical Oncology · 2025
Original publication title
Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.
Source: ObjectivesAbstract: What methods does the paper describe?
A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.
Source: MethodsAbstract: Results
Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).
Source: ResultsAbstract: Conclusion
The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.
Source: ConclusionAuthors’ abstract
Objectives
Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.
Methods
A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.
Results
Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817).
Conclusion
The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.
Supplementary Information
The online version contains supplementary material available at 10.1007/s10147-025-02711-7.
Publication and source details
Original title: Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions
Takuto Hara; Hanako Nishimoto; Tomoaki Terakawa; Yasuyoshi Okamura; Yukari Bando; Hideto Ueki; Kotaro Suzuki; Yoji Hyodo; Jun Teishima; Koji Chiba; Ryosuke Kuroda; Hideaki Miyake
International Journal of Clinical Oncology · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Kobe UniversityOpen Access funding provided by Kobe University.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:49:02.263853+00:00
DOI: 10.1007/s10147-025-02711-7 · PMC11946959